Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).

摘要: Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role echocardiography, cardiac magnetic resonance, nuclear computed tomography management patients. The Imaging Cardio-Oncology Study Groups Heart Failure Association (HFA) European Society Cardiology (ESC) collaboration with (EACVI) Council ESC have evaluated current evidence for value modern cardio-oncology field. most relevant echocardiographic parameters, including global longitudinal strain three-dimensional ejection fraction, are proposed. protocol pre-treatment evaluation specific surveillance algorithms or pathways anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl proteasome inhibitors immune checkpoint presented. indications after completion treatment considered. typical consequences radiation therapy possibility their identification long term also summarized. Special populations discussed female survivors planning pregnancy, carcinoid disease, tumours right heart failure. Future directions ongoing research discussed.